COVID-19 Vaccines: With Anger About Inequity, Is Optimism Misplaced?
From the very early days of the COVID-19 outbreak, public, private and university researchers have been working to develop vaccines. ...
Read moreDetailsFrom the very early days of the COVID-19 outbreak, public, private and university researchers have been working to develop vaccines. ...
Read moreDetailsOn 10 March, the New York Times, basing itself on “closely-held” European Commission documents they were “able to access” in ...
Read moreDetailsRecent announcements of the availability of COVID vaccines have uncovered both the "me-first" nature of humans and countries and at ...
Read moreDetailsThere is light at the end of the tunnel as the UK, armed with COVID-19 vaccines, embarks on its mission ...
Read moreDetailsThere is widespread concern about how fast the current COVID-19 vaccines were produced compared to other past conventional vaccines such ...
Read moreDetailsWith hope of true progress in emerging from the COVID-19 emergency finally on the horizon, ironically, an urgent challenge is ...
Read moreDetailsTo control the COVID-19 pandemic, will a vaccine be enough? This article makes the case that more than a vaccine ...
Read moreDetailsPresident Trump has announced his decision to withdraw the United States from the World Health Organization (WHO) and threatens to ...
Read moreDetails
Impakter informs you through the ESG news site and empowers your business CSRD compliance and ESG compliance with its Klimado SaaS ESG assessment tool marketplace that can be found on: www.klimado.com
Registered Office Address
Klimado GmbH
Niddastrasse 63,
60329, Frankfurt am Main, Germany
IMPAKTER is a Klimado GmbH website
Impakter is a publication that is identified by the following International Standard Serial Number (ISSN) is the following 2515-9569 (Printed) and 2515-9577 (online – Website).
Office Hours - Monday to Friday
9.30am - 5.00pm CEST
stories [at] impakter.com
© 2026 IMPAKTER. All rights reserved.